HER2Low - Mathematical modeling of response towards drugs targeting HER2, EGFR and ERBB3 to personalize breast cancer treatment


Welcome to the project


The HER2Low consortium follows up on high-level expertise, technologies, and large data sets having been generated during the MedSys-funded project BreastSys (2009-2013) and the NGFN-Plus funded project IG-Cellular Systems Genomics (IG-CSG - 2008-2011). The Her2Low consortium combines systematic in vitro validation of targeted therapeutics with a strong mathematical modeling approach and a large-scale analysis of clinical specimens, and includes Roche Diagnostics GmbH, Penzberg, as pharmaceutical partner who will provide novel innovative compounds targeting EGFR/ERBB receptors.



The project started in 2015. It is funded by the Federal Ministry of Education and Research (BMBF) within the framework ‘Systems Medicine – e:MED‘.